Anti g0s2

Antibodies were obtained from multiple sources: anti-GAPDH from Santa Cruz Biotechnology (Santa Cruz, CA, USA), anti-MBD2, anti-collagen I, anti-α-SMA and anti-fibronectin from Abcam (Cambridge, MA, USA), and anti-F4/80, anti-collagen IV, and anti-G0S2 from Proteintech Group (Rosemont, IL, USA). The recombinant human TGF-β1 was obtained from Proteintech Group. The plasmids containing the methylation promoter of the G0S2 CpG-free pCpGI luciferase reporter, MBD2, and mtMBD2 (the deletion of the methylated DNA binding domain), were constructed by the Ruqi Biology Company (Guangdong, Guangzhou, China) according to previously published reports [15 (link), 17 (link)]. The MBD2 siRNA was designed and synthesized by the Ruibo Biology Company (Guangdong, Guangzhou, China) as described in our previously published paper [18 (link)].

The following antibodies were used in this study: an anti-G0S2 (dilution 1:200; Proteintech, IL, USA); an anti-phospho-Histone H2A.X (Ser139) (dilution1:1000; EMD Millipore, Billerica, MA, USA); anti-53BP1 (dilution1:500), anti-RNF168 (dilution1:500), anti-CXCL5 (dilution 1:1000) and anti-Rad51 (dilution 1:1000)(Abcam, Cambridge, MA, USA). The secondary antibodies were from Jackson ImmunoResearch Laboratories (West Grove, PA, USA). Cell culture media and other reagents were from Invitrogen (Carlsbad, CA, USA), Sigma-Aldrich (St. Louis, MO, USA) or Peprotech (Rocky Hill, NJ, USA).